Fast Five Quiz: Early Non–Small Cell Lung Cancer

Daniel S. Schwartz, MD

Disclosures

May 24, 2022

Radiation is a viable treatment option for all patients with early-stage NSCLC who are inoperable, refuse surgery, or are considered high-risk surgical candidates.

PORT is only recommended for cases with positive margins or upstaging to N2.

SABR is also an appropriate treatment option for high-risk surgical candidates. This category includes patients who can tolerate sub-lobar resection but not lobectomy (ie, those who are ≥ 75 years of age or have poor lung function). SABR has shown high primary tumor control rates and overall survival compared with conventionally fractionated radiotherapy. While SABR is not proven equivalent to lobectomy, prospective series have suggested a similar overall and cancer-specific survival between the two approaches.

In early-stage patients who have had a complete resection of an NSCLC with pathologic N0 or N1 stage disease, postoperative radiation is harmful.

Learn more about treatment of NSCLC.

Comments

3090D553-9492-4563-8681-AD288FA52ACE
Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.

processing....